Ind-Swift Laboratories Ltd. (INDSWFTLAB) Share Price Rises 8.68% as Small Cap Stock Gains Today
- August 18, 2026
- Posted by: Lakshit Sharma
- Category: Market
Ind-Swift Laboratories Ltd. traded at Rs 340.5, up 8.68% today, taking its market capitalisation to Rs 2,645.37 crore and placing the small-cap pharma stock firmly in focus.
Ind-Swift Laboratories Ltd. Share Price moved sharply higher on 18 August 2026, with the stock trading at Rs 340.5, up Rs 27.2 or 8.68% from its previous close of Rs 313.3. At this price, the company’s market capitalisation stood at Rs 2,645.37 crore, making it one of the notable small-cap names in today’s Stock Market Today action. As of 18 August 2026 at 12:18:56 PM IST, the verified data confirmed the move, and this article was posted at 12:18:59 PM IST.
For investors searching Ind-Swift Laboratories Ltd. Share Price Today, the key takeaway is straightforward: the stock delivered a strong single-session price rise backed by active volume and a firm intraday range. The available data confirms what happened in the market, but it does not establish a company-specific catalyst behind today’s move. That matters because price action can be clear even when the exact trigger is not confirmed in the supplied company news set.
Ind-Swift Laboratories Ltd. Stock News is therefore being driven today by the verified share price gain, trading activity and the fact that the move was meaningful enough to put the counter among market movers. For investors asking why the stock is trending, the data points to an 8.68% rise, total traded volume of 36,03,970 shares and turnover of Rs 5.37 crore. Important financial metrics also add context: the stock trades at a P/E of 47.53 and P/B of 1.82, while ROE is -0.78 and ROCE is 8.31. The next things to monitor are whether price action holds near the day’s high, how valuation compares with peers, and whether sector context continues to support investor attention, as Univest tracks throughout the session.
Ind-Swift Laboratories Ltd. (INDSWFTLAB) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 340.5 |
| Previous Close | Rs 313.3 |
| Today’s Change | +Rs 27.2 (+8.68%) |
| Day Open | Rs 319.75 |
| Day High | Rs 343.25 |
| Day Low | Rs 318.1 |
| Current Volume (BSE) | 1,57,603 |
| BSE Traded Volume | 1,57,603 |
| NSE Traded Volume | 34,46,367 |
| Combined NSE + BSE Volume | 36,03,970 |
| Turnover | Rs 5.37 crore |
| Market Capitalisation | Rs 2,645.37 crore |
| Market Cap Category | Small Cap |
Ind-Swift Laboratories Ltd. (INDSWFTLAB) traded at Rs 340.5. versus the previous close of Rs 313.3, a rise of 8.68%. The stock opened at Rs 319.75, reached Rs 343.25, touched Rs 318.1. Reported volume was 1,57,603.
Ind-Swift Laboratories Ltd. (INDSWFTLAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 2,645.37 crore |
| P/E Ratio | 47.53x |
| P/B Ratio | 1.82x |
| ROE | -0.78% |
| ROCE | 8.31% |
| EPS | Rs 6.59 |
| Dividend Yield | 0% |
Ind-Swift Laboratories Ltd. was valued at a P/E ratio of 47.53x, a P/B ratio of 1.82x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -0.78% and ROCE of 8.31%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Per-share and shareholder-return metrics included EPS of Rs 6.59, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.
Ind-Swift Laboratories Ltd. Fundamental Analysis shows a business that is now attracting attention because of price action, but the financial ratios present a mixed picture. Valuation is not low versus the industry median on the supplied numbers, while profitability metrics remain below broader healthcare benchmarks. That makes the current move notable, but it also means investors should read today’s strength alongside the company’s exact financial profile.
At Rs 2,645.37 crore in market capitalisation, Ind-Swift Laboratories Ltd. sits well above the industry median market cap of Rs 142.37 crore and the industry average of Rs 492.43 crore in the supplied same-industry benchmark universe of 136 companies. Market capitalisation, however, only signals size and market value; it does not itself confirm business quality. On valuation, the company’s P/E ratio of 47.53 is above the industry median of 26.24 and above the industry average of 39.98, though still far below the maximum observed P/E of 359.13 in the benchmark set. The industry P/E range itself runs from 2.96 to 359.13 across 105 companies.
The stock’s P/B ratio is 1.82, exactly in line with the industry median of 1.82 and below the industry average of 2.49. That places Ind-Swift Laboratories Ltd. Share Price at a book-value multiple that looks more moderate than its earnings multiple. EPS stands at 6.59, which means the current price reflects roughly 47.53 times earnings per share on the supplied data. Dividend yield is 0, so the stock is currently not offering a meaningful historical cash-yield cushion through dividends.
Profitability remains an important point of context. ROE is -0.78, below the industry median of 10.49 and below the industry average of 8.1, which indicates that shareholder returns on the latest supplied basis are weak relative to peers. ROCE is 8.31, also below the industry median of 12.97 and below the industry average of 15.53. In other words, Ind-Swift Laboratories Ltd. Stock Analysis today is being pulled by momentum and price action more than by standout profitability numbers. For readers following Ind-Swift Laboratories Ltd. Financial Results and Ind-Swift Laboratories Ltd. Earnings, that combination makes ownership and peer context especially important, even when the latest move is attracting immediate attention on Univest.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 47.53x |
| Benchmark Median P/E | 26.24x |
| Benchmark Average P/E | 39.98x |
| Benchmark P/E Range | 2.96x to 359.13x |
| Company P/B Ratio | 1.82x |
| Benchmark Median P/B | 1.82x |
| Company ROE | -0.78% |
| Benchmark Median ROE | 10.49% |
| Company ROCE | 8.31% |
| Benchmark Median ROCE | 12.97% |
| Company Market Capitalisation | Rs 2,645.37 crore |
| Benchmark Median Market Cap | Rs 142.37 crore |
Ind-Swift Laboratories Ltd. (INDSWFTLAB) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Ind-Swift Laboratories Ltd. (INDSWFTLAB) has a P/E ratio of 47.53x, which is above the benchmark median of 26.24x, a difference of +81.14%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Ind-Swift Laboratories Ltd. (INDSWFTLAB) has a ROE of -0.78%, which is below the benchmark median of 10.49%, a difference of -107.44%. Ind-Swift Laboratories Ltd. (INDSWFTLAB) has a ROCE of 8.31%, which is below the benchmark median of 12.97%, a difference of -35.93%.
Track today’s top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.
The healthcare and pharmaceuticals backdrop gives useful context for today’s move. Ind-Swift Laboratories Ltd. operates in Healthcare within the Pharmaceuticals & Drugs industry, and the supplied benchmark compares it with 136 companies from the same industry. Relative positioning matters here because the company’s valuation and profitability sit in different places versus the benchmark.
Within the same-industry dataset, Ind-Swift Laboratories Ltd. Share Price reflects a company whose P/E ratio of 47.53 is above both the benchmark median of 26.24 and the benchmark average of 39.98. That suggests the stock is trading at a richer earnings multiple than the middle of the industry pack, though not near the most expensive end because the benchmark maximum reaches 359.13. The company’s P/B ratio of 1.82 matches the industry median exactly and sits below the industry average of 2.49, while the broader P/B range runs from -11.02 to 16.76 across 135 companies.
Profitability comparisons are less favourable. The company’s ROE of -0.78 is below the benchmark median of 10.49 and also below the average of 8.1. ROCE at 8.31 is lower than the median of 12.97 and average of 15.53. Those numbers show that while the market is currently rewarding the stock with a sharp price rise, the business is not screening as a profitability leader versus the Pharmaceuticals & Drugs group on the supplied snapshot.
Size is one area where the company stands out. Its market capitalisation of Rs 2,645.37 crore is much higher than the benchmark median of Rs 142.37 crore and well above the average of Rs 492.43 crore, although still below the benchmark maximum of Rs 2,985.15 crore. The benchmark minimum market cap is Rs 6.06 crore. So in sector terms, Ind-Swift Laboratories Ltd. Latest News today is tied to a stock that is relatively large within its industry sample, moderately priced on book value, more expensive on earnings, and weaker than benchmark medians on ROE and ROCE. That mix helps explain why the counter is being watched closely on Univest and across broader Share Market Today screens.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,985.15 | 170.32 | 0.42 | -2.89 | -0.26 |
| Beta Drugs Ltd. | BETA | 2,827.67 | 65.02 | 10.29 | 18.65 | 22.17 |
| Hikal Ltd. | HIKAL | 2,686.72 | 0 | 2.2 | 15.22 | 16.15 |
| Fredun Pharmaceuticals Ltd. | FREDUN | 2,559.68 | 54.85 | 8.19 | 11.42 | 13.15 |
| Solara Active Pharma Sciences Ltd. | SOLARA | 2,465.73 | 0 | 1.93 | 17.23 | 15.34 |
Ind-Swift Laboratories Ltd. (INDSWFTLAB) has a P/E ratio of 47.53x compared with the displayed peer median of 54.85x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -0.78% compares with a peer median of 15.22% across the companies shown in the table. ROCE stood at 8.31% versus the displayed peer median of 15.34%, providing a capital-efficiency comparison. Ind-Swift Laboratories Ltd. (INDSWFTLAB) has a market capitalisation of Rs 2,645.37 crore. Among the 5 peers shown, 3 have a larger market capitalisation.
Peer comparison shows Ind-Swift Laboratories Ltd. positioned among similarly sized listed pharmaceuticals companies, but with mixed relative metrics. Its market cap of Rs 2,645.37 crore places it near Hikal Ltd. at Rs 2,686.72 crore, Beta Drugs Ltd. at Rs 2,827.67 crore and Dishman Carbogen Amcis Ltd. at Rs 2,985.15 crore, while still above Fredun Pharmaceuticals Ltd. at Rs 2,559.68 crore, Solara Active Pharma Sciences Ltd. at Rs 2,465.73 crore, Sai Parenteral’s Ltd. at Rs 2,438.25 crore, Panacea Biotec Ltd. at Rs 2,429.2 crore, Venus Remedies Ltd. at Rs 2,388.41 crore and NGL Fine-Chem Ltd. at Rs 2,139.2 crore.
On valuation, Ind-Swift Laboratories Ltd. Share Price carries a P/E of 47.53. That is lower than Dishman Carbogen Amcis at 170.32, Sai Parenteral’s at 170.53, Beta Drugs at 65.02 and Fredun Pharmaceuticals at 54.85, but higher than Venus Remedies at 20.48 and NGL Fine-Chem at 31.64. Hikal, Solara and Panacea do not have a supplied peer P/E figure in this dataset, so the most direct takeaway is that Ind-Swift sits in the middle of the available P/E range among named peers rather than at an extreme.
Its P/B of 1.82 is above Dishman’s 0.42 but below Hikal’s 2.2, Solara’s 1.93, Panacea’s 3.02, Sai Parenteral’s 3.12, Venus Remedies’ 3.47, NGL Fine-Chem’s 5.21, Fredun’s 8.19 and Beta Drugs’ 10.29. Profitability is where the gap is clearest. Ind-Swift’s ROE of -0.78 trails Beta Drugs at 18.65, Hikal at 15.22, Fredun at 11.42, Solara at 17.23, Sai Parenteral’s at 13.9, Venus Remedies at 9.85 and NGL Fine-Chem at 27.9; it is only above Dishman’s -2.89 and below Panacea’s 0. ROCE of 8.31 is also below most peers, exceeding only Dishman’s -0.26 and Panacea’s 5.36 while trailing Beta’s 22.17, Hikal’s 16.15, Fredun’s 13.15, Solara’s 15.34, Sai Parenteral’s 12.97 and NGL Fine-Chem’s 33.91. That makes the current share price rise especially interesting because it has arrived despite less impressive profitability metrics than many peers.
Why Investors Are Watching Ind-Swift Laboratories Ltd.
Investors are watching Ind-Swift Laboratories Ltd. Share Price because today’s move combines strong intraday gains, a close-to-high trading pattern and meaningful activity across NSE and BSE. The stock has also moved into a zone where valuation, profitability and peer comparison all deserve closer attention. For traders and long-term market watchers alike, this is the kind of session that can elevate a stock from routine tracking into active discussion within Stocks in News and Top Gainers Today lists on Univest.
- Verified price action: the stock rose 8.68% to Rs 340.5 from Rs 313.3.
- Intraday strength: price traded between Rs 318.1 and Rs 343.25, staying near the high.
- Trading activity: total volume reached 36,03,970 shares, with 34,46,367 on NSE and 1,57,603 on BSE.
- Valuation context: P/E is 47.53 and P/B is 1.82.
- Profitability context: ROE is -0.78 and ROCE is 8.31.
- Sector position: market cap of Rs 2,645.37 crore is well above the industry median.
What investors may monitor next is whether Ind-Swift Laboratories Ltd. Share Price continues to hold above the opening level of Rs 319.75, whether turnover remains supportive, and how the stock’s richer-than-median P/E interacts with weaker-than-median ROE and ROCE. In the absence of a verified company-specific trigger in the supplied data, the durability of price action and its alignment with broader Pharmaceuticals & Drugs positioning become the main variables to track.
About Ind-Swift Laboratories Ltd.
Ind-Swift Laboratories Ltd. is positioned within the Healthcare sector and the Pharmaceuticals & Drugs industry. That means the stock is being assessed by the market alongside other listed drug and pharmaceutical businesses where valuation, profitability, scale and capital efficiency are closely watched. In today’s market context, Ind-Swift Laboratories Ltd. Share Price is not only being discussed as a momentum name but also as a sector stock that sits near the larger end of its same-industry benchmark universe.
Based on the supplied benchmark set, the company’s market capitalisation of Rs 2,645.37 crore places it above the industry average and far above the median, which suggests it is materially larger than a typical company in this specific comparison group. Nearby listed names by market value include Hikal Ltd., Beta Drugs Ltd., Fredun Pharmaceuticals Ltd. and Solara Active Pharma Sciences Ltd. That places Ind-Swift in a competitive listed cluster where investors often compare P/E, P/B, ROE and ROCE alongside daily Stock Performance.
For readers following Ind-Swift Laboratories Ltd. Company News, the most useful business takeaway from the supplied data is that the company belongs to a sector where peer dispersion is wide. In this industry sample, valuation multiples range sharply and profitability outcomes differ meaningfully across companies. That is why both the price rise and the underlying financial ratios matter when assessing Ind-Swift Laboratories Ltd. Share News in the Indian Stock Market.
Track Ind-Swift Laboratories Ltd. Share Price on Univest
Use Ind-Swift Laboratories Ltd. (INDSWFTLAB) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.
Readers tracking Ind-Swift Laboratories Ltd. Share Price can use Univest to follow live share price moves, intraday price action, market cap changes and broader stock analysis in one place. For stocks appearing in top gainer screens, Univest helps users monitor price, turnover, exchange-wise volume, sector context and peer positioning without separating market data from company ratios.
Beyond today’s move, Univest also helps investors track Ind-Swift Laboratories Ltd. Share Price Today alongside valuation metrics such as P/E and P/B, profitability indicators like ROE and ROCE, 52-week levels when available, and broader market insights relevant to NSE News and BSE News. For users following Ind-Swift Laboratories Ltd. Stock News and Ind-Swift Laboratories Ltd. Share Price Live developments, that combination can be useful in understanding whether a stock is moving on isolated momentum, sector rotation or a broader change in market attention.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is Ind-Swift Laboratories Ltd. Share Price today?
Ans. Ind-Swift Laboratories Ltd. Share Price was Rs 340.5 on 18 August 2026 at the time of the update. The stock was up Rs 27.2 from the previous close of Rs 313.3, translating into a gain of 8.68%.
Why is Ind-Swift Laboratories Ltd. rising today?
Ans. The supplied data confirms that Ind-Swift Laboratories Ltd. rose 8.68% today with total traded volume of 36,03,970 shares and turnover of Rs 5.37 crore. However, the verified dataset does not establish a company-specific catalyst behind the move.
What was the intraday range for Ind-Swift Laboratories Ltd. today?
Ans. The stock opened at Rs 319.75, touched an intraday high of Rs 343.25 and a low of Rs 318.1. Trading near Rs 340.5 means Ind-Swift Laboratories Ltd. held close to the upper end of its day’s range.
Is Ind-Swift Laboratories Ltd. a small-cap stock?
Ans. Yes, the supplied classification places Ind-Swift Laboratories Ltd. in the Small Cap category. Its market capitalisation stood at Rs 2,645.37 crore during today’s session, which is the key size reference used in this article.
How much volume was traded in Ind-Swift Laboratories Ltd. today?
Ans. Total traded volume in Ind-Swift Laboratories Ltd. was 36,03,970 shares. Of this, NSE volume was 34,46,367 shares and BSE volume was 1,57,603 shares, showing that most of today’s activity was concentrated on the NSE.
What does the valuation of Ind-Swift Laboratories Ltd. look like?
Ans. Ind-Swift Laboratories Ltd. trades at a P/E ratio of 47.53 and a P/B ratio of 1.82. Its P/E is above the same-industry median of 26.24, while its P/B is exactly in line with the benchmark median of 1.82.
How profitable is Ind-Swift Laboratories Ltd. compared with its industry?
Ans. The company’s ROE is -0.78 and ROCE is 8.31. Both metrics are below the same-industry medians of 10.49 for ROE and 12.97 for ROCE, indicating weaker profitability than the benchmark midpoint.
Does Ind-Swift Laboratories Ltd. pay a dividend?
Ans. The supplied dividend yield for Ind-Swift Laboratories Ltd. is 0. That means the current dataset does not show a meaningful historical dividend yield contribution to the stock’s present market pricing or investor return profile.
How does Ind-Swift Laboratories Ltd. compare with peers on market cap?
Ans. With a market capitalisation of Rs 2,645.37 crore, Ind-Swift Laboratories Ltd. sits close to Hikal at Rs 2,686.72 crore and below Dishman Carbogen Amcis at Rs 2,985.15 crore, while remaining above several other named pharmaceutical peers.
What should investors monitor next in Ind-Swift Laboratories Ltd.?
Ans. Investors may watch whether Ind-Swift Laboratories Ltd. holds above its opening price of Rs 319.75, whether volume stays elevated after today’s 8.68% rise, and how its higher P/E interacts with weaker ROE and ROCE versus industry benchmarks.